Advarra
Latest Posts by Advarra
Clinical Trial Governance: What It Is and Why It Matters
Clinical trial governance is the framework that guides ethical, compliant, and efficient clinical research. It establishes the...
Read More...
What Is the Difference Between an SAE, AE, and UADE in Clinical Trials?
Adverse events (AEs) are untoward medical occurrences in participants receiving a study intervention, regardless of...
Read More...
Q&A with Advarra’s Senior Coordinator of Client Services Rachel Garrett
Rachel Garrett’s career in clinical research has come full circle. After starting her journey at...
Read More...
What Is the Difference Between Monitoring and Auditing in Clinical Trials And Why Do They Matter for Inspection Readiness?
Clinical trial monitoring (CTM) and auditing are both essential quality management activities, but they serve...
Read More...
Why Do Clinical Trial Startup Delays Still Happen Despite More Technology?
Clinical trial study startup has become increasingly technology-enabled, yet sponsors, contract research organizations (CROs), and...
Read More...Updated IRB Handbook Available
Advarra’s IRB Handbook Advarra has updated its Institutional Review Board (IRB) Handbook for Investigators, Institutions,...
Read More...
Improving Clinical Trial Site Collaboration with Connected Study Startup Workflows
Clinical trial study startup requires constant coordination across sponsors, contract research organizations (CROs), research sites,...
Read More...
21 CFR Part 11 and Good Clinical Practice Requirements Explained
Clinical research increasingly depends on electronic systems to support core trial documentation, data handling, and...
Read More...
Q&A with Advarra’s Client Services Team Lead Kyle Naylor
Kyle Naylor didn’t set out to work in the IRB world—but once he found it, he never...
Read More...
Sponsor’s Guide to IRB Approval (Part VI): After IRB Approval: Compliance, Multi-Site Oversight, and Turning Review into a Strategic Advantage
IRB approval is a critical milestone in clinical research, but it isn’t the end of the oversight...
Read More...